BTIG Maintains Buy Rating and Raises Price Target for Caris Life Sciences
BTIG analyst Mark Massaro has reaffirmed a "Buy" rating on Caris Life Sciences and increased the price target from $33 to $38.
Stocks · News reference
Erste Group Downgrades CA Immo to Hold
Erste Group has downgraded its rating for CA Immo to 'Hold' and reduced its price target to 23.6 Euro.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Maintains Hold on Caris Life Sciences, Raises Price Target to $30
Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.